Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies. He has served in operating roles (as founder, CEO and/or Chairman) in building nine Polaris companies. Alan most recently co-founded Seismic Therapeutic, which uses machine learning to accelerate next generation immunology therapies, and Dyno Therapeutics, which uses artificial intelligence to design better viruses for delivery of gene therapies. Prior to Dyno, Alan founded Pandion Therapeutics to focus on tissue-specific immunomodulation for autoimmune disorders and transplantation. In four years from the Polaris seed funding, Pandion became a clinical-stage, public company and was acquired by Merck for $1.85B. Previously, Alan was president and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline. Momenta was acquired by J&J for $6.5B. Alan’s past portfolio companies have collectively been involved in 12 IPOs and M&A exits. Prior to Polaris, Alan was senior vice president of corporate development at Millennium Pharmaceuticals, where he was responsible for generating over $2B in partner funding and acquiring 19 development stage products, including Velcade®, which became the main basis of the company’s $9B acquisition by Takeda. Alan is an active leader with non-profit organizations. He is a recipient of Ernst & Young’s Entrepreneur of the Year award for New England. Alan earned a BA and masters degree in biology and an MBA all from Harvard University and spent two years studying towards an MD at Harvard Medical School.